These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3535018)

  • 21. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer.
    Vantrappen G; Schuurmans P; Rutgeerts P; Janssens J
    Scand J Gastroenterol Suppl; 1982; 80():23-30. PubMed ID: 6761849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colloidal bismuth subcitrate and ranitidine in the short-term treatment of benign gastric ulcer. An endoscopically controlled trial.
    Parente F; Lazzaroni M; Petrillo M; Bianchi Porro G
    Scand J Gastroenterol Suppl; 1986; 122():42-5. PubMed ID: 3465027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate.
    Konturek SJ; Radecki T; Piastucki I; Drozdowicz D
    Digestion; 1987; 37 Suppl 2():8-15. PubMed ID: 3622948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN; Nio CY
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical therapy of peptic ulcer disease.
    McQuaid KR; Isenberg JI
    Surg Clin North Am; 1992 Apr; 72(2):285-316. PubMed ID: 1347960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.
    Miller JP; Hollanders D; Ravenscroft MM; Tweedle DE; Martin DF
    Scand J Gastroenterol Suppl; 1982; 80():39-42. PubMed ID: 6761851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.
    Goodwin CS; Marshall BJ; Blincow ED; Wilson DH; Blackbourn S; Phillips M
    J Clin Pathol; 1988 Feb; 41(2):207-10. PubMed ID: 3280609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical indications and efficacy of colloidal bismuth subcitrate.
    Lambert JR
    Scand J Gastroenterol Suppl; 1991; 185():13-21. PubMed ID: 1957121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Campylobacter pylori--a role in non-ulcer dyspepsia?
    Lambert JR; Dunn K; Borromeo M; Korman MG; Hansky J
    Scand J Gastroenterol Suppl; 1989; 160():7-13. PubMed ID: 2683024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Helicobacter pylori and gastric ulcer therapy: reflections and uncertainties.
    Dobrilla G; Piazzi L; Amplatz S; Benvenuti S; Di Fede F
    Ital J Gastroenterol; 1992 Feb; 24(2):79-84. PubMed ID: 1576367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colloidal bismuth subcitrate in peptic ulcer--a review.
    Tytgat GN
    Digestion; 1987; 37 Suppl 2():31-41. PubMed ID: 3305117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of colloidal bismuth subcitrate on duodenal ulcer relapse.
    Bianchi Porro B; Lazzaroni M; Parente F; Petrillo M
    Scand J Gastroenterol Suppl; 1986; 122():35-8. PubMed ID: 3535020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors influencing the eradication of Helicobacter pylori with triple therapy.
    Graham DY; Lew GM; Malaty HM; Evans DG; Evans DJ; Klein PD; Alpert LC; Genta RM
    Gastroenterology; 1992 Feb; 102(2):493-6. PubMed ID: 1732120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
    Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
    Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of bismuth subsalicylate versus cimetidine on Campylobacter pylori, ulcer healing and rate of recurrence].
    Eberhardt R; Kasper G; Dettmer A; Höchter W; Hagena D
    Med Klin (Munich); 1988 May; 83(12):402-5. PubMed ID: 3043160
    [No Abstract]   [Full Text] [Related]  

  • 36. Colloidal bismuth subcitrate in non-ulcer dyspepsia.
    Khanna MU; Abraham P; Nair NG; Mistry FP; Vora IM
    J Postgrad Med; 1992; 38(3):106-8. PubMed ID: 1303406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
    Eberhardt R; Kasper G
    Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healing of gastric body ulcer with gastroprotective versus antisecretory treatment.
    Jablonská M
    Dig Dis Sci; 1995 Sep; 40(9):2016-8. PubMed ID: 7555458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol).
    Baron JH; Barr J; Batten J; Sidebotham R; Spencer J
    Gut; 1986 May; 27(5):486-90. PubMed ID: 3084345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastric mucosa protection and prostaglandin E2 generation in rats by colloidal bismuth subcitrate (DE-NOL).
    Hall DW; van den Hoven WE
    Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):308-19. PubMed ID: 3473983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.